ANPEP and neoplasm: Emerging evidence indicates that the inhibition of CD13 enzymatic activity—particularly with bestatin, an approved anti-tumor adjuvant drug with good safety, or with monoclonal antibodies including WM15, SJ1D1, and MY7—has antineoplastic effects via not only modulation of the immune response but also direct suppressive activity against tumor cells.